{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:42:43Z","timestamp":1792194163388,"version":"4.4.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the optimal therapy for patients with intermediate-risk AML after first complete remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Settings, and Participants<\/jats:title><jats:p>This investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)\u2013matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), <jats:italic>NPM1<\/jats:italic> and <jats:italic>CEBPA<\/jats:italic> variation status, and donor type (unrelated vs related).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>End points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (<jats:italic>P<\/jats:italic>\u2009=\u2009.22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (<jats:italic>P<\/jats:italic>\u2009=\u2009.001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Nonrelapse mortality at 2 years after primary allogeneic HCT was 9% (95% CI, 5%-19%) and 2% (95% CI, 0%-11%) after consolidation chemotherapy (<jats:italic>P<\/jats:italic>\u2009=\u2009.005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Primary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01246752\">NCT01246752<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.7605","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T16:02:11Z","timestamp":1675958531000},"page":"519","source":"Crossref","is-referenced-by-count":53,"title":["Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia"],"prefix":"10.1001","volume":"9","author":[{"given":"Martin","family":"Bornh\u00e4user","sequence":"first","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"},{"name":"National Center for Tumor Diseases, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[{"name":"Helios Klinikum, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Department for Hematology and Cellular Therapy, University Hospital, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[{"name":"Department for Hematology and Oncology, University Hospital, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz P.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Halle Martin Luther, University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[{"name":"University Hospital Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[{"name":"University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"R\u00f6sler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Immunotherapy, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[{"name":"Klinikum N\u00fcrnberg, Paracelsus Medizinische Privatuniversit\u00e4t, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[{"name":"University Hospital Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[{"name":"University Hospital Munich-Grosshadern, Department of Internal Medicine III, Ludwig-Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[{"name":"University Hospital Munich-Grosshadern, Department of Internal Medicine III, Ludwig-Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[{"name":"Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael","family":"Alakel","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"coi220096r1","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/ajh.v95.11","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management.","volume":"95","author":"Estey","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"coi220096r3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"coi220096r4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality.","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi220096r5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia.","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"29","key":"coi220096r6","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm\u2013combined prospective analysis by the German AML Intergroup.","volume":"30","author":"B\u00fcchner","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220096r7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"coi220096r8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse.","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"coi220096r9","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","article-title":"Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.","volume":"28","author":"Schlenk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi220096r10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi220096r11","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"coi220096r12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts.","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"22","key":"coi220096r13","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"coi220096r14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"3","key":"coi220096r15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"issue":"24","key":"coi220096r16","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi220096r17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why Test for Proportional Hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"coi220096r19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"16","key":"coi220096r20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"12","key":"coi220096r21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"1","key":"coi220096r22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission.","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"coi220096r23","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","article-title":"Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.","volume":"5","author":"Fasslrinner","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"coi220096r24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"coi220096r25","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"12","key":"coi220096r26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease.","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi220096r27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi220096r28","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN).","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi220096r29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"coi220096r30","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2009.1485","article-title":"Donor availability and clinical trials for allogeneic stem cell transplantation.","volume":"302","author":"B\u00fcchner","year":"2009","journal-title":"JAMA"},{"key":"coi220096r2","unstructured":"Cancer Stat Facts. Leukemia\u2014acute myeloid leukemia (AML). Accessed January 15, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"coi220096r18","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2020. https:\/\/www.r-project.org\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2801295\/jamaoncology_bornhuser_2023_oi_220096_1681755656.40095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:41:44Z","timestamp":1682008904000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2801295"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.7605","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}